Uzbekistan arrests four people over cough syrup deaths in India

Two of the detained were senior employees of the Scientific Center for Standardization of Medicines, who circumvented the proper testing procedures for the Doc-1 Max cough syrup

cough syrup, medicine, cold
Marion Biotech said last month, shortly after the series of deaths, that it had halted production of the syrup
Reuters Tashkent
1 min read Last Updated : Jan 06 2023 | 5:12 PM IST
Uzbekistan has arrested four people in an investigation into the deaths of 19 children who consumed cough syrup made by Indian drug maker Marion Biotech, the Uzbek state security service said on Friday.

Two of the detained were senior employees of the Scientific Center for Standardization of Medicines, who circumvented the proper testing procedures for the Doc-1 Max cough syrup, it said.

Two others were executives of the Quramax Medikal company that imported the Marion Biotech drugs.

Marion Biotech said last month, shortly after the series of deaths, that it had halted production of the syrup.

Uzbekistan's health ministry had said the syrup contained a toxic substance, ethylene glycol, and was administered in doses higher than the standard dose for children, either by their parents, who mistook it for an anti-cold remedy, or on the advice of pharmacists.

The Uzbekistan case follows deaths of at least 70 children in Gambia that a parliamentary committee had linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals. The company denied any wrongdoing and Indian government inspectors found no contamination in test samples.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :UzbekistanCough syruphealth care

Next Story